These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 31145289)

  • 21. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.
    Song F; Hu B; Cheng JW; Sun YF; Zhou KQ; Wang PX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
    Cell Death Dis; 2020 Jul; 11(7):573. PubMed ID: 32709873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
    Brada M; Hoang-Xuan K; Rampling R; Dietrich PY; Dirix LY; Macdonald D; Heimans JJ; Zonnenberg BA; Bravo-Marques JM; Henriksson R; Stupp R; Yue N; Bruner J; Dugan M; Rao S; Zaknoen S
    Ann Oncol; 2001 Feb; 12(2):259-66. PubMed ID: 11300335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anlotinib: First Global Approval.
    Syed YY
    Drugs; 2018 Jul; 78(10):1057-1062. PubMed ID: 29943374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial.
    Huang J; Xiao J; Fang W; Lu P; Fan Q; Shu Y; Feng J; Zhang S; Ba Y; Zhao Y; Liu Y; Bai C; Bai Y; Tang Y; Song Y; He J
    Cancer Med; 2021 Mar; 10(5):1681-1689. PubMed ID: 33586360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Procarbazine and CCNU Chemotherapy for Recurrent Glioblastoma with MGMT Promoter Methylation.
    Kim SH; Yoo H; Chang JH; Kim CY; Chung DS; Kim SH; Park SH; Lee YS; Yang SH
    J Korean Med Sci; 2018 Jun; 33(24):e167. PubMed ID: 29892208
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Temozolomide rechallenge in recurrent glioblastoma: when is it useful?
    Franceschi E; Lamberti G; Visani M; Paccapelo A; Mura A; Tallini G; Pession A; De Biase D; Minichillo S; Tosoni A; Di Battista M; Cubeddu A; Bartolini S; Brandes AA
    Future Oncol; 2018 May; 14(11):1063-1069. PubMed ID: 29741106
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continuous dose-intense temozolomide and cisplatin in recurrent glioblastoma patients.
    Wang Y; Kong X; Guo Y; Wang R; Ma W
    Medicine (Baltimore); 2017 Mar; 96(10):e6261. PubMed ID: 28272232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia.
    Brandes AA; Basso U; Reni M; Vastola F; Tosoni A; Cavallo G; Scopece L; Ferreri AJ; Panucci MG; Monfardini S; Ermani M;
    J Clin Oncol; 2004 May; 22(9):1598-604. PubMed ID: 15117981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Activity and Safety of Anlotinib for Patients with Extremity Desmoid Fibromatosis: A Retrospective Study in a Single Institution.
    Zheng C; Zhou Y; Wang Y; Luo Y; Tu C; Min L
    Drug Des Devel Ther; 2020; 14():3941-3950. PubMed ID: 33061299
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience.
    Scoccianti S; Detti B; Sardaro A; Iannalfi A; Meattini I; Leonulli BG; Borghesi S; Martinelli F; Bordi L; Ammannati F; Biti G
    Anticancer Drugs; 2008 Jul; 19(6):613-20. PubMed ID: 18525321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
    Shi F; Guo H; Zhang R; Liu H; Wu L; Wu Q; Liu J; Liu T; Zhang Q
    Neuroscience; 2017 Mar; 346():298-308. PubMed ID: 28147244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
    J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib.
    Chen D; Xu J; Zhao Y; Chu T; Zhong H; Han B; Zhong R
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):401-406. PubMed ID: 31691871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme.
    Muhic A; Poulsen HS; Sorensen M; Grunnet K; Lassen U
    J Neurooncol; 2013 Jan; 111(2):205-12. PubMed ID: 23184145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apatinib and temozolomide in children with recurrent ependymoma: A case report.
    Zhao S; Shen Z; Li J; Shi L; Zhang N
    Medicine (Baltimore); 2022 Sep; 101(37):e30529. PubMed ID: 36123900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Retrospective Cohort Study Evaluates Clinical Value of Anlotinib in Persistent, Metastatic, or Recurrent Cervical Cancer After Failure of First-Line Therapy.
    Yang H; Sun S; Mei Z; Xiang Q; Yang C; Chen M; Xie C; Zhou Y; Qiu H
    Drug Des Devel Ther; 2021; 15():4665-4674. PubMed ID: 34815663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular analysis of a recurrent glioblastoma treated with bevacizumab.
    Furuta T; Nakada M; Misaki K; Sato Y; Hayashi Y; Nakanuma Y; Hamada J
    Brain Tumor Pathol; 2014 Jan; 31(1):32-9. PubMed ID: 23504126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma.
    Minniti G; Armosini V; Salvati M; Lanzetta G; Caporello P; Mei M; Osti MF; Maurizi RE
    J Neurooncol; 2011 Jul; 103(3):683-91. PubMed ID: 21052773
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
    Lassman AB; van den Bent MJ; Gan HK; Reardon DA; Kumthekar P; Butowski N; Lwin Z; Mikkelsen T; Nabors LB; Papadopoulos KP; Penas-Prado M; Simes J; Wheeler H; Walbert T; Scott AM; Gomez E; Lee HJ; Roberts-Rapp L; Xiong H; Ansell PJ; Bain E; Holen KD; Maag D; Merrell R
    Neuro Oncol; 2019 Jan; 21(1):106-114. PubMed ID: 29982805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma.
    Silvani A; De Simone I; Fregoni V; Biagioli E; Marchioni E; Caroli M; Salmaggi A; Pace A; Torri V; Gaviani P; Quaquarini E; Simonetti G; Rulli E; D'Incalci M;
    J Neurooncol; 2019 May; 142(3):455-462. PubMed ID: 30726533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.